Irradiated autologous multicellular vaccine isolated from fresh c | 32499
Immunotherapy: Open Access

Immunotherapy: Open Access
Open Access

ISSN: 2471-9552

Irradiated autologous multicellular vaccine isolated from fresh carcinoma induces multiple-target antitumor immunity

International Conference on Tumor & Cancer Immunology and Immunotherapy

July 28-30, 2016 Melbourne, Australia

Chunju Fang, Xiyan Mu, Yuquan Wei and Hanshuo Yang

Sichuan University, China

Posters & Accepted Abstracts: Immunother Open Acc

Abstract :

Introduction: X-irradiated autologous tumor cells with adjuvant have been proved as an effective vaccine which induces reduction of tumor recurrence in some cancer patients but the mechanism remained to be further demonstrated. In a murine model we investigated the composition, efficacy and mechanism of irradiated autologous multicellular vaccine isolated from fresh carcinoma without any manipulations. Material & Method: Single-cell suspensions isolated from tumor tissues were cultured for 24 hours to acquire adherent cells, whose contents were analyzed by flow cytometry. X-irradiated autologous multicellular vaccine (AMCV) or PBS were then injected into mice of protective CT26 and LLC models. Adoptive transfer experiments, depletion of immune cell subsets, 51chromium-release assay, IHC of tumor sections and flow cytometry of spleen and tumor cells were carried out to demonstrate different immune mechanisms. Results & Discussion: AMCV, including tumor cells, epithelial cells, myeloid-derived suppressor cells (MDSCs), provoked protective anti-tumor activity, which was dependent on CD8+ T cells. Compared with PBS group, AMCV not only increased the percentages of CD8+IFN-�?³+ and CD4+IFN-�?³+ T-cells in spleen and tumor, but also decreased the percentages of MDSCs in spleen. The 51Cr-release assay showed that spleen lymphocytes from mice immunized by AMCV exhibited a higher cytotoxicity against tumor cells, mixed cells derived from carcinoma and endothelial cells (also confirmed in IHC of tumor tissues with CD31). Conclusions: AMCV was able to elicit anti-tumor immunity through multiple target including killing tumor cells and inhibiting angiogenesis, which might be a new strategy for cancer therapy in patients.

Biography :